Overview
Acadia Pharmaceuticals is a biopharmaceutical company commercializing Nuplazid (pimavanserin), the first FDA-approved drug specifically for hallucinations and delusions associated with Parkinson's disease psychosis. They are also developing treatments for Alzheimer's disease psychosis and Rett syndrome.
More in Neuropharmaceuticals
Latest industry news
Cala Health Launches Next-Generation TAPS Therapy Wearable Nationwide for Tremor and Parkinson's Patients
2026-10-11 · Product
A New Neurotech Startup Launches to Challenge Sam Altman's Merge Labs in the BCI Race
2026-10-10 · Industry
Butterfly Network Teams Up With Bridge Neurotech to Chase Ultrasound-Based Brain-Computer Interfaces
2026-10-09 · Industry
Paradromics Hits Four-Year Mark for Stable Neural Recording in Landmark BCI Durability Milestone
2026-10-08 · Research
Company details
Category
💊 Neuropharmaceuticals
Location
San Diego, USA
Funding
Public · NASDAQ: ACAD
Website
www.acadia-pharm.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →